title: [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
abstract: The selective strogen receptors modulators (SERMs) were initially developed as antistrogens for the treatment of breast cancer, but their unusual properties have led to their use in the treatment and prevention of other diseases as well. SERMs bind the strogen receptor (ER) and modulated ER-mediated gene transcription. Tamoxifen is an effective treatment for hormone responsive breast cancer and can prevent breast cancer in high-risk women. Raloxifene was approved for the prevention and treatment of osteoporosis in postmenopausal women, also appears to prevent breast cancer. Other SERMs are in development, with the goal of improving efficacy and reducing toxicity.
authors.affiliation: Servicio de Investigación y Docencia, Maternidad Concepción Palacios, Caracas, Venezuela. catireteran@hotmail.com
authors.forename: José
authors.initials: J
authors.lastname: Terán Dávila
authors.forename: Alejandro D
authors.initials: AD
authors.lastname: Teppa Garrán
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use*; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride